Furthermore, integrating metabolomics with network pharmacology enhances our understanding of the multi-target nature of Chinese medicine formulations
Want to see where the next opportunities are emerging
Details of metabolites identification and its levels of confidence are provided in Supplemental Tables S1 & S2
preparation of any injectable medicine must be performed by or under direct supervision of a qualified healthcare professional
Time period What may be noticeable What the evidence supports Weeks 1-4 Satiety, appetite changes, nausea, bowel changes, early scale movement Early tolerability period, not the main efficacy endpoint window Weeks 4-12 More consistent appetite suppression and early weight trend Direction of response may become clearer, but individual variance is high Weeks 12-24 Clinically meaningful separation becomes easier to evaluate Phase 2 primary endpoint at 24 weeks showed dose-dependent weight loss Weeks 24-48 Major body-weight reduction window in Phase 2 48-week Phase 2 secondary endpoint showed the largest published Phase 2 changes Weeks 68-104 Longer-term Phase 3 and extension outcomes TRIUMPH program endpoints measure durability over longer windows Weeks 1-4: Early Signals, Not Final Results The first few weeks are usually the wrong window for judging full retatrutide results
This prolongs incretin activity, increases postprandial insulin secretion from pancreatic beta cells, decreases glucagon secretion, delays gastric emptying, and lowers blood glucose levels (National Center for Biotechnology Information, 2023a)
